Bone mineral density in patients with rheumatoid arthritis treated with infliximab

Por Vis, M, Voskuyl, A, Wolbink, G, Dijkmans, B, Lems, W, t for
Publicado em 2005

Adverse events in patients with rheumatoid arthritis treated with infliximab in daily clinical practice

Por Neven, N, Vis, M, Voskuyl, A, Wolbink, G, Nurmohamed, M, Dijkmans, B, Lems, W
Publicado em 2005

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis

Por Wolbink, G, Voskuyl, A, Lems, W, de Groot, E, Nurmohamed, M, Tak, P, Dijkmans, B, Aarden, L
Publicado em 2005

High levels of human anti‐human antibodies to adalimumab in a patient not responding to adalimumab treatment

Por Bartelds, G M, Wolbink, G J, Stapel, S, Aarden, L, Lems, W F, Dijkmans, B A C, Nurmohamed, M T
Publicado em 2006

Inhibition of human complement by beta-glycyrrhetinic acid.

Por Kroes, B H, Beukelman, C J, van den Berg, A J, Wolbink, G J, van Dijk, H, Labadie, R P
Publicado em 1997

Changes in the serum concentration and the glycosylation of human alpha 1-acid glycoprotein and alpha 1-protease inhibitor in severely burned persons: relation to interleukin-6 lev...

Por Pos, O, van der Stelt, M E, Wolbink, G J, Nijsten, M W, van der Tempel, G L, van Dijk, W
Publicado em 1990

Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation

Por de Vries, M K, Wolbink, G J, Stapel, S O, de Groot, E R, Dijkmans, B A C, Aarden, L A, van der Horst‐Bruinsma, I E
Publicado em 2007

Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti‐infliximab in responders and non‐responders to therapy for rheumatoid arthritis

Por van der Laken, C J, Voskuyl, A E, Roos, J C, van Walsum, M Stigter, de Groot, E R, Wolbink, G, Dijkmans, B A C, Aarden, L A
Publicado em 2007

Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up

Por Vogelzang, E. H., Hebing, R. C. F., Nurmohamed, M. T., van Kuijk, A. W. R., Kruijff, J. W. F., l’Ami, M. J., Krieckaert, C. L. M., Wolbink, G.
Publicado no PLoS One (2018)

A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tiss...

Por van Kuijk, A W R, Gerlag, D M, Vos, K, Wolbink, G, de Groot, M, de Rie, M A, Zwinderman, A H, Dijkmans, B A C, Tak, P P
Publicado em 2008

The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.

Por Baars, J. W., Hack, C. E., Wagstaff, J., Eerenberg-Belmer, A. J., Wolbink, G. J., Thijs, L. G., Strack van Schijndel, R. J., van der Vall, H. L., Pinedo, H. M.
Publicado em 1992

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor α expression in the synovium

Por Wijbrandts, C A, Dijkgraaf, M G W, Kraan, M C, Vinkenoog, M, Smeets, T J, Dinant, H, Vos, K, Lems, W F, Wolbink, G J, Sijpkens, D, Dijkmans, B A C, Tak, P P
Publicado em 2008

Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis

Por Peters, M J L, Vis, M, van Halm, V P, Wolbink, G J, Voskuyl, A E, Lems, W F, Dijkmans, B A C, Twisk, J W R, de Koning, M H M T, van de Stadt, R J, Nurmohamed, M T
Publicado em 2007